Merozyne Therapeutics AB recently initiated a project with the goal of developing a pharmaceutical treatment to address laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A) through supporting the research that Madeleine Durbeej-Hjalt and Virginie Carmignac conducted at Lund University. Merozyne Therapeutics AB has been established very recently by several entrepreneurial life science firms based at the Medicon…
News
The 5th Annual Getzlaf Golf Shootout to benefit CureDuchenne will take place on September 12th at Sutra Lounge in Costa Mesa, California and September 13th at the Monarch Beach Golf Links in Dana Point, California. The event will be hosted by the captain of the Anaheim Ducks, …
In a new study entitled “Under-recognition of Low Blood Pressure Readings in Patients with Duchenne Muscular Dystrophy,” researchers determined for the first time how blood pressure is affected in patients with duchenne muscular dystrophy. They report a significant portion of DMD patients exhibit low blood pressure, and highlight the need for clinicians…
The FSH Society, a Massachusetts-based charity supporting research into facioscapulohumeral muscular dystrophy (FSHD), has announced that it recently completed the 2nd edition of the FSHD Trial Preparedness Workshop, which was held between May 29 and 30, 2015 at the University of Rochester Medical Center in Rochester, New York. The workshop included over 50 stakeholders from around…
A new study published in the journal Human Molecular Genetics revealed a new therapeutic approach that could potentially alter the progression of muscle damage and dysfunction in patients with myotonic dystrophy. The study is entitled “TWEAK/Fn14, a pathway and novel therapeutic target in myotonic…
In a recent study published in Oncotarget, researchers found an inverse correlation between the level of muscle fibrosis, utrophin and the number of revertant myofibers in Duchenne Muscular Dystrophy (DMD). Results from this study reveal common links between the fibrotic and utrophin-synthesis pathways and offer new insights into…
A new collaborative group involving academic and industry researchers and patient advocacy groups conducted a large-scale study to find serum biomarkers for Duchenne muscular dystrophy (DMD). The study was recently published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…
The Muscular Dystrophy Association (MDA) has begun another season of its well known summer camp, marking its 60th year in operation. The MDA summer camp aims to support families by hosting thousands of children struggling against muscular dystrophy and similar conditions that seriously limit their mobility and muscular strength. The summer camp assists kids in helping them…
Managing muscular dystrophy (MD) is not an easy task, and it depends not only medical intervention, but also on methods to improve patients’ quality of life. “Supporting People & Pets through Opportunity and Training” (SPPOT) is a community interest company focused on that purpose, helping to train…
Germany’s Federal Joint Committee (G-BA) published a positive Benefit Assessment for Translarna (ataluren), including an evaluation of the benefits of the drug in treating nonsense mutation Duchenne Muscular Dystrophy (nmDMD) in ambulatory patients older than five years. The therapy, which was developed by PTC Therapeutics, was rated “three” — or minor additional benefits…
Recent Posts
- Being good at handling a medical scare doesn’t make this DMD mom happy
- DM1 therapy shows promise over year of testing, trial data suggest
- Pursuing meaningful work while living with Duchenne muscular dystrophy
- Bionews survey highlights key drivers of mental health distress in MD
- My lesson about what not to do when you’re a DMD caregiver